PRTA at a glance
PROTHENA CORP PUBLIC LTD CO (PRTA, SEC CIK 1559053) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), PROTHENA CORP PUBLIC LTD CO (PRTA) reported revenue of $9.7 million (down 92.8% from FY2024) and a net loss of $244.1 million. Diluted EPS was -$4.53.
- The most recent insider open-market purchase reported on Form 4 was by SCULLY WILLIAM P on November 17, 2026 of 50,000 shares at $8.09 per share.
- In the last 90 days, PRTA insiders reported 13 open-market purchases ($9.8M) and 0 open-market sales ($0) on Form 4, a net purchase of $9.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $9.7M
- −92.8% vs prior year
- Insiders · 90 days
- 13 buys · 0 sells
- Net +$9.8M
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly highlighted financial trigger: $50.0 million coramitug milestone earned March 9, 2026, with remaining milestones uncertain
- Liquidity risk: $271.4 million cash and equivalents may not fund continued development beyond the next twelve months
- Regulatory compliance risk: EU GDPR violations could incur fines up to €20 million or 4% of global annual turnover
- Operational risk: Roche, Novo Nordisk, and BMS control ongoing clinical development of prasinezumab, coramitug, and moponetug
- Competitive risk: Biosimilar competition could arise sooner if BPCIA exclusivity protections are shortened or unavailable
Management Discussion & Analysis
- Q3 revenue $0.6M, down 74% YoY from $2.4M, entirely collaboration revenue
- Operating expenses $19.4M, down 54% YoY from $42.7M, driven by lower R&D and G&A
- Nine-month revenue $52.7M, up $43.1M YoY, including $50.0M Novo Nordisk milestone
- Cash $271.4M vs $307.5M at December 31, 2025, with $8.1M operating cash use and $26.8M share repurchases
- 2026 operating and investing cash use expected at approximately $18M to $23M; cash sufficient for at least twelve months
AI summary of the PRTA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Prothena announced third-quarter 2026 financial results for the period ended September 30, 2026
- Full operating results and management commentary are in Exhibit 99.1, the company’s November 5, 2026 press release
Item EX-99.1: Item EX-99.1
- Q3 net loss $16.5M, or $0.32 per share, improved from $36.5M and $0.68 in Q3 2025
- Nine-month revenue $52.7M, including a $50.0M Novo milestone tied to coramitug’s Phase 3 trial
Item 1.02: Termination of a Material Definitive Agreement
- Bristol Myers Squibb ending PRX019 development after Phase 1, despite benign safety and dose-dependent pharmacodynamic results
- PRX019 license terminates January 28, 2027, eliminating eligibility for up to $617.5 million in milestones and future royalties
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Chief Development Officer Chad J. Swanson resigns effective October 9, 2026
- Departure to strategic partner creates leadership transition risk
AI summaries of PRTA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PRTA
Don't miss the next PRTA filing
- Alerts as it files. A push when PRTA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PRTA, by share count.
- Ask anything. An AI agent that reads every PRTA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| SCULLY WILLIAM P | Buy | Nov 17, 2026 | 50,000 | $8.09 |
| SCULLY WILLIAM P | Buy | Nov 9, 2026 | 140,000 | $8.53 |
| SCULLY WILLIAM P | G | Nov 6, 2026 | 916,444 | - |
| SCULLY WILLIAM P | G | Oct 27, 2026 | 566,444 | - |
| SCULLY WILLIAM P | Buy | Oct 23, 2026 | 50,000 | $8.07 |
| SCULLY WILLIAM P | Buy | Oct 22, 2026 | 100,000 | $8.19 |
| SCULLY WILLIAM P | Buy | Oct 14, 2026 | 10,000 | $8.46 |
| SCULLY WILLIAM P | Buy | Oct 13, 2026 | 100,000 | $8.35 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $91.4M | $135.2M | $9.7M |
| Operating Income | -$191.0M | -$154.6M | -$214.6M |
| Net Income | - | -$122.3M | -$244.1M |
| Op. Margin | -209.1% | -114.4% | -2216.4% |
| Net Margin | - | -90.5% | -2520.6% |
| Balance Sheet | |||
| Total Assets | $696.4M | $547.1M | $326.8M |
| Equity | $561.4M | $486.9M | $280.5M |
| ROE | - | -25.1% | -87.0% |
| Per Share | |||
| EPS | $-2.76 | $-2.27 | $-4.53 |
| Cash Flow | |||
| Operating CF | -$133.9M | -$150.1M | -$163.6M |
Source: XBRL data in PROTHENA CORP PUBLIC LTD CO (PRTA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
PRTA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 29, 2026 | - | - | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 4 | Oct 26, 2026 | - | - | - |
| 4 | Oct 15, 2026 | - | - | - |
| 4 | Oct 9, 2026 | - | - | - |
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Oct 2, 2026 | - | Analysis | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PRTA SEC filings: frequently asked questions
Are PRTA insiders buying or selling?
In the last 90 days, PROTHENA CORP PUBLIC LTD CO (PRTA) officers, directors and 10% owners reported 13 open-market purchases worth $9.8 million by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
What was PRTA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), PROTHENA CORP PUBLIC LTD CO (PRTA) reported revenue of $9.7 million (down 92.8% from FY2024) and a net loss of $244.1 million. Diluted EPS was -$4.53. The figures come from the XBRL data in the 10-K.
What did PRTA report in its latest 8-K?
PROTHENA CORP PUBLIC LTD CO (PRTA) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Prothena announced third-quarter 2026 financial results for the period ended September 30, 2026.
What are the latest PRTA SEC filings?
PROTHENA CORP PUBLIC LTD CO (PRTA) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 19, 2026.
What is PRTA's SEC CIK number?
PROTHENA CORP PUBLIC LTD CO (PRTA)'s SEC Central Index Key (CIK) is 1559053. EDGAR lists every PRTA filing under that number.
Ask anything about PRTA
The research agent reads PRTA's filings, financials, insider trades and 13F holders, then answers with sources.